Cannformatics, an early-stage biotechnology startup, has identified 22 new potential lipid-based Cannabis-Responsive biomarkers in the saliva of children with autism spectrum disorder (ASD).
The Biomarkers
All 22 biomarkers shifted toward the physiological range of typically developing children following successful medical cannabis treatment. These biomarkers include central nervous system lipids that are primarily associated with cellular activity in the brain indicating medical cannabis’ potential to impact neuron function in children with ASD.
These discoveries continue the company’s progress towards launching a personalized medicine service as a resource to healthcare providers and patients wanting to use cannabinoid-based medicines and products to treat complex medical conditions.
The Journal
The company published its findings in the journal Cannabis and Cannabinoid Research in a paper titled, “The potential of salivary lipid-based Cannabis-Responsive biomarkers to evaluate medical cannabis treatment in children with ASD.”
This paper is the second to come from the company’s ASD Pilot study. The first paper, published in December 2021, established Cannabis-Responsive biomarkers as a universal tool for measuring medical cannabis impact. Together the two papers demonstrate the potential for saliva-based Cannabis-Responsive biomarkers to be a tool for both clinicians treating patients with medical cannabis and life science companies developing next-generation…
Original Author Link click here to read complete story..
Cannformatics, an early-stage biotechnology startup, has identified 22 new potential lipid-based Cannabis-Responsive biomarkers in the saliva of children with autism spectrum disorder (ASD).
The Biomarkers
All 22 biomarkers shifted toward the physiological range of typically developing children following successful medical cannabis treatment. These biomarkers include central nervous system lipids that are primarily associated with cellular activity in the brain indicating medical cannabis’ potential to impact neuron function in children with ASD.
These discoveries continue the company’s progress towards launching a personalized medicine service as a resource to healthcare providers and patients wanting to use cannabinoid-based medicines and products to treat complex medical conditions.
The Journal
The company published its findings in the journal Cannabis and Cannabinoid Research in a paper titled, “The potential of salivary lipid-based Cannabis-Responsive biomarkers to evaluate medical cannabis treatment in children with ASD.”
This paper is the second to come from the company’s ASD Pilot study. The first paper, published in December 2021, established Cannabis-Responsive biomarkers as a universal tool for measuring medical cannabis impact. Together the two papers demonstrate the potential for saliva-based Cannabis-Responsive biomarkers to be a tool for both clinicians treating patients with medical cannabis and life science companies developing next-generation…